Lion Point Capital, LP’s Fennec Pharmaceuticals Inc Position
Does Lion Point Capital, LP own Fennec Pharmaceuticals Inc (FRX)? Yes — 112.4K shares worth $691,469 (+4.13% of its 13F portfolio) as of Q1 2026.
Position Value
$691,469
Q1 2026
Shares
112.4K
% of Portfolio
+4.13%
Quarters Held
12
currently held
Position History FRX
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 112.4K | $691,469 | +4.13% |
| Q4 2025 | 112.4K | $865,742 | +4.48% |
| Q3 2025 | 123.0K | $1M | +6.54% |
| Q2 2025 | 195.7K | $2M | +11.03% |
| Q1 2025 | 195.7K | $1M | +7.60% |
| Q4 2024 | 195.7K | $1M | +6.48% |
| Q3 2024 | 215.0K | $1M | +2.39% |
| Q2 2024 | 170.0K | $1M | +1.89% |
| Q1 2024 | 170.0K | $2M | +1.06% |
| Q4 2023 | 110.0K | $1M | +0.62% |
| Q3 2023 | 110.0K | $826,100 | +0.37% |
| Q2 2023 | 110.0K | $971,300 | +0.44% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Lion Point Capital, LP’s full portfolio or all institutional holders of FRX.